Growth Metrics

Soleno Therapeutics (SLNO) Change in Accured Expenses (2016 - 2019)

Historic Change in Accured Expenses for Soleno Therapeutics (SLNO) over the last 7 years, with Q4 2019 value amounting to $968000.0.

  • Soleno Therapeutics' Change in Accured Expenses rose 52857.14% to $968000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $1.7 million, marking a year-over-year increase of 42305.3%. This contributed to the annual value of $1.6 million for FY2024, which is 1239.73% up from last year.
  • According to the latest figures from Q4 2019, Soleno Therapeutics' Change in Accured Expenses is $968000.0, which was up 52857.14% from $442000.0 recorded in Q3 2019.
  • In the past 5 years, Soleno Therapeutics' Change in Accured Expenses registered a high of $968000.0 during Q4 2019, and its lowest value of -$317000.0 during Q1 2016.
  • Its 5-year average for Change in Accured Expenses is $182205.6, with a median of $147500.0 in 2018.
  • Over the last 5 years, Soleno Therapeutics' Change in Accured Expenses had its largest YoY gain of 395000.0% in 2018, and its largest YoY loss of 41428.57% in 2018.
  • Quarter analysis of 5 years shows Soleno Therapeutics' Change in Accured Expenses stood at $467626.0 in 2015, then skyrocketed by 49.8% to $700486.0 in 2016, then tumbled by 100.57% to -$4000.0 in 2017, then skyrocketed by 3950.0% to $154000.0 in 2018, then soared by 528.57% to $968000.0 in 2019.
  • Its last three reported values are $968000.0 in Q4 2019, $442000.0 for Q3 2019, and $81000.0 during Q2 2019.